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
	
The re6purposing of the anti6anginal drug perhexiline (PHX) has resulted in 
symptomatic improvements in heart failure (HF) patients. The inhibition of carnitine 
palmitoyltransferase61 (CPT61) has been proposed as the primary mechanism underlying 
the therapeutic benefit of PHX. This hypothesis is contentious. 

We reviewed the primary literature and patent landscape of PHX from its 
initial development in the 1960s through to its emergence as a drug beneficial for HF. We 
focused on its physico6chemistry, molecular targets, tissue accumulation and clinical dosing. 
		
Dogma that the beneficial effects of PHX are due primarily to potent 
myocardial CPT61 inhibition is not supported by the literature and all available evidence point 
to it being extremely unlikely that the effects of PHX occur via this mechanism. 	 
PHX is much more likely to be an inhibitor of surface membrane ion channels and also to 
have effects on other components of cellular metabolism and reactive oxygen species 
(ROS) generation across the cardiovascular system. However, the possibility that 	 
effects of PHX on CPT61 underpin disproportionately large effects on myocardial function 
cannot be entirely excluded, especially given the massive accumulation of the drug in heart 
tissue. 
 
Keywords: perhexiline, carnitine palmitoyltransferase, heart failure, metabolism, modulation, 
therapy 
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Article highlights  
 
  
 
• In contrast to recent dogma, we propose that it is unlikely that the therapeutic 
benefit of perhexiline in patients with HF is due, in large part, to the inhibition of 
CPT61. 
• All available data suggests that PHX is a drug of low potency, low specificity and 
low selectivity that interacts with multiple surface membrane ion channels and 
other intracellular components that impinge on cellular metabolism and the 
generation of reactive oxygen species (ROS).  
• The possibility that 	 effects of PHX on CPT61 underpin disproportionately 
large effects on myocardial function cannot be excluded, especially given the 
massive accumulation of PHX in myocardial tissue. 
• A scheme is described that considers the pleiotropic effects of PHX via the 
inhibition of surface membrane ion channels and its accumulation in mitochondrial 
membranes.  
• The combined action of PHX on multiple targets throughout the cardiovascular 
system probably underpins the symptomatic improvements in HF patients. 
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	
As defined by Yancy and colleagues “HF is a complex clinical syndrome that results from 
any structural or functional impairment of ventricular filling or ejection of blood”.1 It is a global 
epidemic, affecting 10% of individuals over the age of 65 years and its clinical progression 
results in mortality of 50% within 4 years of diagnosis.1 Contemporary approaches, which 
aim to correct left ventricular ejection fraction (LVEF) and halt or normalize the progression 
of myocardial dysfunction are sub6optimal and involve the modulation of neurohumoral 
targets including β6adrenergic (β6AR) blockers, suppression of the renin6angiotensin6
aldosterone (RAA) system (angiotensin II receptor (ATIIR), angiotensin6converting enzyme 
(ACE), aldosterone antagonism), vasodilators and diuretics. Whilst these conventional 
therapies primarily modulate upstream regulators of the circulatory system, there are newer 
strategies that aim to target more ‘myocardially6focused’ elements including the drivers of 
progressive contractile and arrhythmogenic events that occur 		 cardiac cells265 and even 
approaches that replace or repair damaged myocardium.6  
 We have previously described normal myocardial cell signaling in terms of the 
synchronization of coupled systems.769 For example, there is functional integration between 
cellular ion fluxes and metabolism in which the dynamic cycling of intracellular Ca2+ is 
critically modulated by ATP6dependent processes, and many events in ATP synthesis are 
Ca2+6dependent. Consequently, the functional deterioration of the myocardium in long6term 
cardiac diseases such as HF is associated with the progressive desynchronization within 
and between numerous linked processes. Using the example above, disease6linked 
derangement in Ca2+ signaling, which is considered a major feature of HF pathogenesis, 
impacts on ATP bioavailability and vice versa.7, 8  
If we consider then that approaches that aim to correct HF6linked Ca2+ signaling 
dysfunction7, 8, 10614 may positively influence other ‘linked’ systems such as metabolism, there 
is substantial merit in developing new therapies that alter cellular metabolism with a view to 
rescuing cellular Ca2+ handling. An emergent approach to normalizing cardiac performance 
in HF therefore is the direct modulation of the myocardial metabolic state and drugs that 
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promote a switch in substrate utilization from fatty acid oxidation (FAO) to glycolysis (so6
called ‘metabolic modulators’) are keenly sought.15618 
Important problems in developing new therapeutic approaches though include the 
limitations of rational drug design and sometimes prohibitory regulatory and financial barriers 
which have led to creative solutions for finding new niches for existing drugs in the clinical 
landscape.4, 19623 ‘Repositioning’, ‘repurposing’ and ‘reappropriating’ have become buzzwords 
in the contemporary drug development framework.  
In this article, we consider some of these issues relating to perhexiline (PHX; 26(2,26
dicyclohexylethyl)piperidine), a drug reappropriated from the treatment of angina pectoris 
(AP) and reported to be a clinically useful drug in the management of HF. The history of 
PHX, from its initial development as an L6type Ca2+ channel blocker24629, its efficacy in AP296
35, its contraindications, withdrawals and now its emergence in treating HF has been 
comprehensively reviewed previously.15, 18, 36 However, its mechanism of action remains 
contentious and here we consider, with specific reference to the patent landscape, how the 
apparent disconnect between the measureable clinical benefits of PHX in HF and the 
molecular underpinnings of its actions can be reconciled.  
 
( !!"
!	#$  
The hallmark metabolic dysfunction in HF is the intrinsic shift from FAO (aerobic) to glucose 
(anaerobic) metabolism.37642 This transition is likely the consequence of a lack of adequate 
cardiac tissue oxygenation in the diseased state6 although this is questionable in non6
ischaemic HF (DCM)436 but it may, to some extent, represent an adaptatory mechanism to 
preserve myocardial function. Although glucose metabolism yields much less ATP than FAO 
(a theoretical yield of 38 moles ATP for the complete oxidation of glucose versus 129 moles 
ATP per mole of palmitate)44, it is a more oxygen efficient mode of energy production 
yielding 3.17 moles ATP/moles atomic oxygen versus 2.8 moles of ATP/moles atomic 
oxygen for FAO of palmitate.44 Approaches that aim to promote this ‘oxygen sparing’ effect 
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would also be coupled to the reduced flux of intermediates through the tricarboxylic acid 
(TCA or Krebs cycle) which would decrease the generation of reactive oxygen species 
(ROS) and minimize lactate production thereby preventing acidosis (Figure 1). Potentially, 
the combined effects of reduced ROS and normalized pH may contribute more to the 
beneficial effect of ‘metabolic modulation’ than considerations regarding the lower net yield 
of ATP. Since metabolism is enmeshed with numerous other cellular process (e.g. 
mTORC1/AMPK6mediated nutrient sensing modules involved in cell growth and 
autophagy)45648, there are other considerations for ‘metabolic modulation’ beyond ATP 
synthesis and consumption and energy substrate utilization. 
Singh and colleagues have recently reviewed candidates for therapeutic metabolic 
modulation including the TCA cycle, pyruvate dehydrogenase (PDH), malonyl CoA6
decarboxylase (MCD), fatty acid oxidation (FAO), insulin sensitivity and carnitine 
palmitoyltransferase (CPT61).18 Of these, it is CPT61, an outer6mitochondrial membrane6
resident enzyme, that has received the most attention. There are three isoforms of CPT61 
(1A, 1B and 1C); CPT1A and B share 63% sequence homology and are abundantly 
expressed in a wide variety of tissues, whereas CPT61C is restricted to the brain.49 CPT61B 
is the predominant isoform in the heart and exhibits a lower affinity for its substrate carnitine 
than CPT61A (approximately 156fold) but is more sensitive to inhibition by the endogenous 
inhibitor malonyl co6A inhibition than CPT1A.49 CPT61 catalyzes the formation of acyl 
carnitine, via the transfer of the acyl group of a long6chain fatty acyl6CoA from coenzyme A 
to carnitine50. Acyl carnitine subsequently transfers from the cytosol into the mitochondrial 
inter6membrane space to undergo CPT626catalyzed conversion back to acyl6CoA which 
undergoes catabolic beta6oxidation in the mitochondrial matrix to yield acetyl6CoA which 
then enters the TCA cycle (Figure 1). In principle therefore, CPT61 inhibition, which 		 is 
mediated by of malonyl Co6A levels (Figure 1), reduces mitochondrial import and oxidation 
of fatty acids, promotes glycolysis via reduced acetyl6CoA production and decreases ROS 
and lactate accumulation (Figure 1) albeit at the expense of ATP production.  
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 One approach to therapeutically target CPT61 activity is the development of 
heterocyclic and piperidine compounds that inhibit malonyl6CoA decarboxylase (MCD) which 
leads to an accumulation of malonyl6CoA51, 52, the endogenous inhibitor of CPT61 		
(Figure 1).53 We return to the subject of malonyl6CoA inhibition of CPT61, and the 
implications for adjunctive PHX6mediated inhibition, in section 4. 
However, in the context of treating chronic myocardial dysfunction, it is the direct 
pharmacologic inhibition of CPT61 that has captured the imagination. In a compelling series 
of clinical studies, PHX (hailed as the ‘forerunner of metabolic agents’16) has been shown to 
produce beneficial effects in patients with refractory HF symptoms despite otherwise optimal 
medical therapy 54, symptomatic hypertrophic cardiomyopathy (HCM)55, and non6ischaemic 
dilated cardiomyopathy (DCM).56 Such symptomatic improvements include reduced New 
York Heart Association (NYHA) classification of disease severity 54, 55, increased peak 
oxygen uptake (VO2 max) 
54, 55, improvements in quality6of6life scores54, 56, 57 and six6minute 
walk tests57. Whether these functional benefits are dependent on improved myocardial 
function (e.g. left ventricular ejection fraction; see 54 vs. 56), or interestingly skeletal muscle 
function54, has yet to be fully established. Moreover, although these investigations evidence 
beneficial changes in the phosphocreatine/ATP ratio which suggest generalized 
improvements in cardiac energetics, in their study of DCM patients Beadle  failed to find 
evidence of altered cardiac substrate utilization56. This finding is at odds with the principal 
dogma of earlier studies on PHX that its main effect is to promote the shift from FAO to 
glycolysis.25, 29, 58, 59 It is necessary therefore to harmonize the therapeutic benefit of PHX 
with its mechanism of action and in sections 3 to 6 we address this issue by reference to the 
patent literature and the physico6chemical determinants of CPT61 inhibition. 
 
	%&'#$

Notwithstanding some of the disparate effects of PHX in patients with different forms of 
chronic heart disease54656, an important question is to what extent does CPT61 inhibition 
contribute to the clinical improvement measured in these patients. The first patent relating to 
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 8
PHX and CPT61 was filed by Horowitz and Kennedy60 and sought to protect the use of a 
screening assay for discriminating compounds on the basis of CPT61 inhibition. Such 
compounds were proposed to be useful in treating ‘ischaemic conditions’.  
On the basis of demonstrating improved clinical endpoints in PHX6treated patients, 
Frenneaux and colleagues have filed a suite of patents pertaining to its efficacy in ischaemic 
and non6ischaemic HF61, HF with preserved ejection fraction (HFpEF)62 and hypertrophic 
cardiomyopathy (HCM).63 These patents all include the phrase “Perhexiline (26(2,26
dicyclohexylethyl)piperidine) is a known anti6anginal agent that operates principally by virtue 
of its ability to shift metabolism in the heart from free fatty acid metabolism to glucose, which 
is more energy efficient”, but it is striking that none of these patents claim that the clinical 
benefit of PHX is because of CPT61 inhibition.  
However, the CPT616centricity of the proposed mechanism of PHX action persists 
and a recent patent filing from the University of Aberdeen seeks to protect intellectual 
property (IP) around a fluorinated PHX6derivative useful for treating a very broad range of 
“disorders that are ameliorated by the inhibition of carnitine palmitoyltransferaseNN”.64 
With regard to the progression of HF being a consequence of the deterioration of 
linked systems (see section 1), it is interesting to note that the patent on PHX effect in 
ischaemic and non6ischaemic HF61 states that “metabolic manipulation with PHX is effective 
in modifying not an inciting influence, but rather the common programme of the chronic heart 
failure”. It is plausible therefore that the metabolic dysfunction in HF is secondary to the 
abnormality in some other linked system and that PHX may be useful in modifying the 
chronic metabolic remodelling associated with HF progression and not in preventing disease 
onset. 
 
	(&!!)#$
*
The symptomatic improvement in HF following PHX administration has been linked to a 
broad range of phenomenological descriptions including cGMP6dependent potentiation of 
platelet sensitivity to NO32, 35, 65, vasodilatory effects66, 67, positive inotropic actions via 
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troponin6C68, circulating levels of ROS69 and insulin sensitization.70 However, assigning the 
molecular target(s) of PHX that underlies these phenomena has proved more difficult.  
The patent filing of Horowitz and Kennedy60, together with the companion paper from 
the same group71, used an 		 (intact) mitochondrial assay to robustly make the case 
that PHX (and also amiodarone) was a CPT61 inhibitor. It was here that the concept that the 
“major biochemical basis of the anti6ischaemic effect of PHX is inhibition of CPT61” was 
born. Measuring drug IC50 values in this type of assay is prone to influence from several 
variables, including the levels of the protein in the tissue, local concentration of drug and the 
accessibility of its binding site (i.e. isolated mitochondrial preparations). To our knowledge, 
the binding affinity of PHX for CPT61 has not been determined. We acknowledge that it is 
difficult to experimentally mimic 		 the precise conditions that may be important 
determinants of drug6target interaction 		. Although we consider investigations using 
recombinant CPT isoforms expressed in methylotrophic 			 yeast to constitute 
the most direct measurements of PHX6CPT interaction72, 73, the likelihood of PHX binding 
multiple targets (1) makes it impossible at present to assign the relative contributions of PHX 
modulation of individual targets to the downstream effects. As has been noted previously, 
these issues relating to ‘holistic’ assessments of drug action are presently beyond the 
resolution of contemporary assays.22 
On the basis of Kennedy’s early work on CPT1 inhibition by PHX71, the review 
literature on PHX perpetuates the idea that the primary mechanism of action the drug is 
through CPT61 inhibition (for example, “the identification of CPT61 as perhexiline’s major 
biochemical site of inhibition”15). Given the paucity of supporting data, the evidence base for 
this assertion is not convincing (Table 1).
PHX shares common properties with other Na+6, K+6 and Ca2+6 ion channel blockers, 
many of which are recognized anti6arrhythmic drugs (Table 2), including its appreciable 
hydrophobicity and an ionizable nitrogen which is positively charged at neutral pH (7.4). In 
this regard, PHX is chemically different to etomoxir, which is an exemplar CPT inhibitor49 
and in a quasi6exhaustive review of CPT inhibitor chemistry, PHX, oxfenicine (where the 
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active metabolite is 46hydroxyphenylglyoxylate (HPG)) and amiodarone were clearly 
categorized as “miscellaneous compound[s] reported to be CPT inhibitors”.49 Ceccarelli  
concluded that in view of PHX’s extremely weak inhibition of CPT61 it was “highly 
questionable that the effects are due to CPT1 inhibition”.49 The chemical properties of PHX 
would also suggest relatively poor selectivity and specificity.74 This is corroborated by the 
data in Table 1 which emphasizes the multiplicity of PHX targets and importantly, all 
available data point to PHX exerting its  potent effect on CPT61 (Table 1). However, it is 
recognized that functional pleiotropy (i.e. drug promiscuity), which we have previously 
considered as ‘magic shotguns’ versus ‘magic bullets’75, can be beneficial.76 This is 
discussed this further in section 7. 
In consideration of the other reported targets of PHX (Table 1), the relevance of 
competitive inhibition of CPT61 by PHX 		 (characterized by an IC50 of 77 QM determined 
in isolated mitochondria membrane preparations71) may be questioned. Moreover, the 
inhibition of CPT61 by malonyl6CoA is 106100 times more potent (IC50 of 0.6 6 6.3 QM 
depending on the local concentration of palmitoyl6CoA (25 QM or 150 QM, respectively))77 
with a recent 	 study suggesting that malonyl6CoA produces a 33% inhibition of CPT61 
activity in resting (non6stimulated) muscle.77 However, it may be important 		 that the 
actions of PHX on CPT61 are mechanistically different to those of malonyl co6A and 
oxfenicine (IC50 of CPT61 inhibition = 11 SM
78) and it has been suggested that PHX acts at a 
protected mitochondrial site not amenable to proteolysis i.e. in the plane of the membrane.15, 
71, 79 It is also intriguing that the specific counterion used in the preparation of the clinical 
formulation of a drug may have a profound impact on its physico6chemical properties, 
including logP.80 This is especially pertinent for maleate which has been shown to directly 
influence cellular metabolism via promoting the utilization of glucose and the accumulation of 
fatty acids.81, 82 The contribution of the maleate ‘counterion’ to the effects attributable to PHX, 
especially in the context of altered metabolism, warrants further investigation.83 
Recent proteomic and metabolic studies have corroborated a complex effect of PHX 
on metabolism.84, 85 In a study of mice treated for 4 weeks at steady6state PHX plasma 
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concentration, Yin and colleagues reported the activation of the pyruvate dehydrogenase 
complex (PDH) (Figure 1) and a “rebalancing of carbon and nucleotide phosphate fluxes, 
fuelled by increased lactate and amino acid uptake, to increase metabolic flexibility and 
maintain cardiac output”.84 Furthermore, Ceccarelli determined a greater potency of PHX on 
ketone body (KB) generation and beta6oxidation (FAO) inhibition in rat and human 
hepatocytes (IC50 = 14.8 and 22.4 QM, respectively) than on CPT61 inhibition (IC50 > 100 
QM).49 Together these data advance the idea that the therapeutic effects of PHX may be 
due, in some part to 	 metabolic modulation, but the notion of PHX being a potent 
inhibitor of CPT61 needs further evaluation.  
To this end, the effects of PHX on reduced ROS may be more attributable to direct 
inhibition of NADPH oxidase (NOX2) rather than effects on cardiac energetics 86 Also, 
Unger and colleagues reported that in non6ischaemic working rat hearts, “perhexiline 
increases myocardial efficiency by a mechanism(s) that is largely or entirely independent of 
its effects on CPT”.87 
 
	+&'!!
A well6known consequence of longer term (unmonitored) PHX administration (typically > 3 
months)88 is lipidosis6induced hepato6 and neuro6toxicity, hypoglycaemia and weight loss.31, 
34, 89694 However, there is now a more complete understanding of the risk factors 
predisposing individuals to adverse effects, including patient6specific CYP2D6 status.95698 
Oxidative metabolism of PHX produces mono6 and di6hydroxylated metabolites. The 
predominant metabolite detected in plasma 6 	64 hydroxyperhexiline 6 is found at 
concentrations higher than PHX.99, 100 Those individuals with CYP2D6 insufficiency (‘poor 
metabolizers’) have a reduced capacity to form this metabolite101 and thus PHX is 
contraindicated in these individuals. This association between drug chirality and toxicity is 
also important99, 100, 102 since there is reported stereoselectivity of (+) and (6) enantiomers to 
metabolism.95, 100, 101 The asymmetry of the C2 of the piperidine ring means that PHX is 
administered as a racemic mixture of (+) and (6) enantiomers. The (+)6PHX enantiomer is 
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cleared more slowly from the plasma1036105 and is associated with a more pronounced toxicity 
profile.104, 106 Sallustio’s recent patent on the use of (6)6PHX seeks to negate the issue of 
toxicity and other problems possibly linked to the complex mixture of different stereoisomers 
and metabolites of unknown efficacy arising from administration of the unresolved racemic 
mixture.106, 107  
Awareness of the issues considered above, coupled with optimised dosing regimens 
and plasma drug monitoring to maintain a therapeutic range between 0.15 60.6mg / L 
(approximately 0.562 QM)1086110, have led to the re6introduction of PHX in the UK on a named 
patient basis. However, phospholipidosis6linked toxicity (similar to that observed with chronic 
amiodarone exposure)111 raises the issue of accumulation in tissues which requires further 
consideration of PHX from a physico6chemical perspective.  
PHX is very poorly water soluble (limit of solubility of 0.0608 mg / L; approximately 
0.2 QM) and highly lipophilic6 the logP, the octanol6water partition coefficient used as a 
measure of lipophilicity is 6.2, comparable to that of amiodarone, a drug for which 
membrane accumulation is a causal factor in its serious adverse effects (Table 2). Given the 
very low water solubility of PHX, at safe clinical dosing levels (i.e. plasma concentration of 
drug between 0.15 and 0.6 mg / L), the ratio of [PHX]unbound to [PHX]bound would be 
approximately 40:60% and 10:90%, respectively. Importantly then, since under normal 
(monitored) dosing conditions PHX would already be at its limit of solubility, any increase in 
the concentration of PHX upwards of reportedly ‘toxic’ plasma levels of drug (i.e. > 0.6 mg / 
L) would simply mean that more of the drug existed in a bound state in the plasma. The 
notion therefore that monitoring plasma levels of PHX does not give a true indication of drug 
distribution was recently confirmed by the remarkable finding of Drury and colleagues that 
the concentrations of PHX in human right atria and left ventricles were 6.0 and 10.0 mg / kg, 
respectively6 approximately 1006 to 1706 times higher than the amount of PHX unbound 
(‘free’) in the plasma.112 The massive accumulation of drug was corroborated by the same 
authors in a recent study.103  
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So how does PHX accumulate to such high levels in tissue? We describe the 
possible mechanisms that underpin accumulation of the drug in section 6, but it is first 
necessary to consider the impact that drug ionization state will have on the modes of 
transfer across cellular membranes. The pKa of PHX is 10.58 so 99.9% of the drug would 
exist in the charged (cationic) form in the plasma at pH7.4. As discussed above then under 
therapeutic dosing regimens (i.e. at its limit of solubility of 0.06 mg / L), effectively all of the 
drug would exist in the cationic form (≈ 99.9%, 0.05994 mg / L) with the neutral form present 
at just 0.00006 mg / L. If the tiny amount of the neutral form of the drug (≈ 60 ng / L in the 
plasma) was the only species able to transfer across the cell surface membrane, myocardial 
concentrations of the drug at 6 – 10 mg /kg 103, 112 would establish an intracellular:plasma 
concentration gradient of 100,000:1. It is inconceivable that such massive accumulation 
could be supported by simple passive transfer of the neutral form of the drug from the 
plasma into cells, even if one considers that the neutral species that does partition across 
the surface membrane would be immediately protonated (to its cationic form) in the cellular 
environment (Figure 2). This therefore raises the likelihood that other factors contribute to 
the cellular accumulation of PHX. First, the peculiar hydrophobicity properties of PHX may 
promote the integration of the cationic species into the membranes. Second, and probably 
the most likely contributor to the cellular accumulation of PHX, is that organic ion transporter 
proteins (TP) present in the surface membrane are likely involved in the active uptake of the 
cationic form of the drug into cells, as has been reported to occur with amiodarone, a drug 
with a very similar physico6chemical profile to PHX.113 
 
	,&
Some of the acute effects of PHX, at least in experimental systems, are rapidly reversible. In 
chick embryo ventricular cells, Barry  described the negative inotropic effect of PHX 
measured after a seven minute equilibration to reach steady state drug effects which was 
quickly reversed by washing out the drug.114 However, as described in section 5, under 
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conditions of clinical dosing it appears that the therapeutic (and in some cases the 
hazardous) effects of PHX are primarily mediated by longer term accumulation inside cells.  
Figure 2 describes some of the mechanisms that may contribute to PHX 
accumulation in the myocardium. Any cellular accumulation would be dependent on factors 
that disturb the free equilibrium between the cells and plasma and thus the only way that the 
drug can accumulate to levels grossly in excess of the plasma concentration is if there is an 
intracellular binding target or the relatively stable association of the drug with lipid 
membranes. Consequently, the scenario depicted in Figure 2A which describes the loading 
of cytoplasm with high [PHX]free, and which may be commonly thought of as ‘cytoplasmic 
accumulation’, cannot occur. Also refuting the possibility that high cytoplasmic [PHX]free (as 
depicted in Figure 2A) occurs 		 is that under these conditions the surface membrane 
Na+6, K+6 and Ca2+ channels would also be exposed to high concentrations of drug. Since 
the mode of channel inhibition is through drug interaction at the cytoplasmic face of the 
channel and in consideration of the comparatively low IC50 values for PHX6channel 
interaction (Table 1) these channels would be profoundly inhibited. This would result in 
catastrophic impact on heart rhythm and rate, effects that are conspicuously absent in PHX 
treated patients (although a heart rate lowering effect of PHX in other species has been 
reported115, 116).  
Cellular accumulation could however feasibly occur via a mechanism that involves 
PHX binding to cytoplasmic moieties which would allow the drug to partition against its 
concentration gradient (Figure 2B). It is important to note though that in these 
circumstances, high levels of intracellular accumulation would not translate into high levels 
of drug concentration, and the levels of ‘free’ PHX in the cytoplasm would be low (Figure 
2B). It is possible though that low levels of ‘free’ PHX in the cytoplasm, which would 
predominantly be in the cationic form (see above), would still be sufficient to modulate 
surface membrane ion channel activity (Table 1).  
There is evidence of preferential association of PHX with phospholipid membranes, 
particularly those characterized by regional ‘charge’ gradients (e.g. H+ gradients across 
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mitochondrial and lysosomal membranes)59, 71, 117 which may contribute to intra6cellular 
localization of very high drug concentrations at these organelles. Such a mechanism could 
also conceivably lead to cellular ‘trapping’ of PHX. As to whether the protonation of PHX in 
the cytoplasm of the cell would lead to a buffering of H+ ions and as a consequence 
modulate cellular pH, we believe this to be unlikely. In our view, any effect of PHX on pH 
normalization should remain focused on the relative balance of pyruvate6to6lactate which is 
dictated by the schemes outlined in Figure 1. 
From its lipophilicity profile, the partitioning of PHX into membranes (especially 
mitochondrial membranes once it is protonated inside the cell) is likely to be rapid and it has 
been reported that high concentrations of drug applied extracellularly (25 QM) affected 
metabolism and promoted cellular toxicity within 24h.89 Even more striking is the direct 
biochemical evidence for the decreased utilization of fatty acids (by approximately 35%) in 
rat hearts perfused with 2 QM PHX within a one6hour experimental window.59 The timings of 
these effects point to either rapid cellular accumulation or alternatively, to an acute indirect 
modulation of metabolism (i.e. downstream from inhibition of surface6membrane ion 
channels). 
There are two plausible scenarios in which longer6term accumulation of PHX could 
modulate CPT61 and its other targets at the IC50s described in the literature (Table 1). First, 
if CPT61 and the other targets are the target for PHX binding (Figure 2C). Under these 
conditions one would expect marked inhibition of surface membrane ion channel fluxes and, 
for the reasons outlined above, this is unlikely to occur 		. Specifically with regards 
CPT61 though, the scheme described in Figure 2C may seem unlikely because of the 
endogenous competition from the much more potent malonyl CoA and the very high IC50 of 
PHX (>100 QM in a 	 expression system)49 (Table 1). However, PHX interacts with 
CPT61 via an atypical mechanism that possibly involves interaction within the plane of the 
membrane (see section 4, above) and thus could reach very high concentrations in the 
vicinity of CPT61. Such massively localized accumulation of PHX at CPT61 would constitute 
‘active6site concentration’111 although little is known as to how this phenomena may 
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influence drug6target inhibition. The idea that PHX preferentially partitions in the 
extravascular pericardial compartment or pericardial fat (as occurs with amiodarone)49 is not 
supported by Drury’s study which determined very high levels of PHX accumulation in 
myocardial tissue obtained via biopsy of patients undergoing coronary artery bypass surgery 
which was presumably free of pericardial fat.112  
The second scenario for chronic PHX accumulation, and in our view the most likely 
mechanism that reconciles the low potency of PHX for CPT61 with its actions on this target 
and on other ion channels is shown in Figure 2D. In this scheme PHX distribution is 
heterogeneous and (1) it accumulates in the membrane, (2) it interacts directly with CPT61 
and (3) some of the drug is free in the cytoplasm as a result of an equilibrium set up 
between cytoplasmic binding factor(s) and the bulk hydrophilic environment. All of these 
distributions though are subject to saturability such that eventually all targets/binding 
partners would be PHX bound or associated with intracellular moieties. After dosing 
previously drug naïve patients at a plasma concentration of approximately 1 QM, 
concentrations of PHX in ventricular tissue reached over 10 mg / kg (approximately 36 QM) 
within 30 days of drug administration (median 8.5 days).112 Moreover, although the PHX 
accumulation in these tissues was directly correlated with plasma concentration of drug and 
length of therapy there was no evidence of saturability of uptake over the time of study.112 In 
a more recent follow6up, the conclusion of Chong and colleagues that PHX does exhibit 
saturability is not supported by their data (see103, Fig 2A and B). Given these observations, it 
is difficult to conceive of how long6term PHX administration, even with maintenance of 
plasma concentrations of the drug at around 1 QM, would not lead to the steady 
accumulation of toxic levels of PHX. However, one of the authors of this article (ZY) has 
been treating some HF patients with PHX for over ten years; this chronic administration of 
PHX is well tolerated and the symptomatic improvements are substantial. Clearly, there are 
factors that affect PHX tolerance and accumulation that remain incompletely understood. 
Finally, one commonly overlooked feature of CPT61 is its widespread tissue 
distribution. CPT61 is expressed at lower levels in the heart than in other tissues including 
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kidney, liver, pancreas, lung and intestine.49 The issues considered above would presumably 
apply equally in these tissues and the reported patterns of hepato6, neuro6 and gastrotoxicity 
are consistent with this idea. 
 
	-./ 
In this article we have considered issues relating to the chemistry, mechanism of action, 
tissue accumulation and clinical benefits of PHX. An improved understanding of PHX drug 
safety and monitoring has underpinned its use in patients with HF and the evidence for its 
therapeutic efficacy in this context is strong. However, the disparate clinical endpoints 
following PHX administration in HF arising from distinct aetiologies (e.g. ischaemic6 versus 
non6ischaemic HF) suggest that the mechanism of action of PHX is complex and not fully 
understood. 
 The more recent literature is dominated by the concept that the beneficial effects of 
PHX are due primarily to its inhibition of myocardial CPT61. Contrary to this dogma, having 
reviewed all the available evidence, including key patents relating to the clinical usage of 
PHX and detailed studies of drug6target interactions, we suggest that it is very unlikely that 
the effects of PHX are due to CPT61 inhibition. Furthermore, over the last twenty years 
or so the preoccupation with CPT61 as the most relevant target of PHX has overshadowed a 
substantive body of older, but very credible evidence, for PHX affecting the extra6cardiac 
circulatory system. It is entirely likely that the therapeutic benefits of PHX in HF are due to 
combined cardiac and vascular effects (e.g. vasodilation).  
 The robustness of some of the statements made regarding PHX and CPT61 inhibition 
is at stark odds with the limited evidence supporting such a mechanism that can be found in 
the literature. In a recent and detailed analysis of CPT61 inhibitor chemistry, Ceccarelli 
effectively debunked the idea that perhexiline is a physiologically relevant CPT61 inhibitor.49 
However, we cannot completely exclude the possibility that minor effects of PHX on CPT61 
underpin disproportionately large effects on myocardial function, especially since there is 
massive accumulation of the drug in atrial and ventricular tissue. To reconcile these 
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arguments, it is plausible that the symptomatic improvements determined in HF patients are 
due to the fact that PHX is not a good CPT61 inhibitor in an 		 setting and that any 
clinical utility is dependent on only partial CPT61 inhibition. Horowitz and colleagues, who 
first positioned PHX as an exemplar CPT61 inhibitor60, 71, have previously acknowledged this 
likelihood, albeit from the perspective of toxicity rather than efficacy6 the adverse reactions 
encountered with perhexiline and indeed those of other CPT61 inhibitors (e.g. etomoxir) are 
the consequence of excessive CPT61 and hence fatty acid metabolism inhibition”.71 Like 
PHX, the antianginal trimetazidine exerts multiple effects via multiple mechanisms (see 
e.g.118); it is a potent inhibitor of beta6oxidation of free fatty acids119, but only a weak CPT1 
inhibitor120, and has been shown to reduce fibrosis121 and to normalise aberrant Ca2+ 
handling in cardiomyocytes obtained from post6injured myocardium.122 Moreover, the finding 
that etomoxir, the only drug considered as a 	 CPT61 inhibitor by Ceccarelli and 
colleagues49 evoked severe hepatoxicity 123 would also suggest that appreciable inhibition of 
CPT61 		 is not clinically useful. Thus although there is undeniable merit in developing 
new ‘metabolic modulators’, approaches that aim to develop selective CPT61 targeted drugs 
with enhanced biological half6life and/or increased potency should be viewed with caution. It 
is also likely that targets other than CPT61 present alternative strategies for regulating 
myocardial FA fluxes.49, 124 
 The linked nature of the composite systems involved in metabolic regulation (i.e. the 
complex synchronization of ion handling, metabolite sensing, substrate utilization, energy 
supply6and6demand) means that reconciling any effects on altered energy metabolism with 
the specific effects on discrete molecular targets is extremely difficult. With this in mind, the 
evidence that PHX effects are mediated by its actions on a multiple ion channels and other 
cellular components that impinge on aspects of cellular metabolism is more convincing 
(Table 1). In Figure 2D, we propose a scheme which considers the effects of PHX via 1) the 
inhibition of surface membrane ion channels via low levels of free drug in the cytoplasm and 
2) accumulation in mitochondrial membranes which leads to a highly localized concentration 
of drug in the vicinity of CPT61 resulting in its partial inhibition.  
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 In summary, we suggest that due to its physico6chemical properties, PHX is a drug of 
low potency, low specificity and low selectivity. As a result, the pleiotropic actions of PHX on 
a diverse range of molecular targets, some of which remain to be properly defined, 
contribute to its therapeutic benefit in HF. 
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Table 1. Rank order of PHX inhibitory potency. 
 
 
 
 
Rank 
order of 
potency 
Target IC50 
((M) 
Experimental system Ref. 
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Kv1.5, K
+ channel carrying the ultra6rapid delayed rectifier current (IKur); HEK, human 
embryonic kidney; CHO, Chinese hamster ovary; HERG, K+ channel encoded by the human 
ether6a6go6go related gene that carries the rapid delayed rectifier current (IKr). 
 
1 Kv1.5 (IKur) 
 
2 Recombinant Kv1.5 in HEK cells 125 
2 NADPH 
oxidase 
2 6 6 Neutrophils, cardiac fibroblasts 69, 86 
3 HERG 6 6 8 Recombinant HERG in CHO cells 126, 127 
 
4 ‘Fast’ Na+ 
channels 
10 6 30 Rat heart membrane / 
synaptosomes 
128 
5 Ca2+ 
channels 
1 6 50 Rat heart membrane 128 
6 NADH6CoQ 
(Complex I) 
23 6 68 Rat heart mitochondria 129 
7 Na+/K+6
ATPase 
50 Rat brain homogenate 117 
8 CPT62 73 6 79 Recombinant 			 
membrane /  
rat heart mitochondria 
49, 79 
9 CPT61 77 6 
>100 
Rat heart mitochondria /  
recombinant 			 
membrane 
49, 79 
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Drug IUPAC name Structure logP Primary 
target 
Verapamil (RS)626(3,46
dimethoxyphenyl)656{[26
(3,46dimethoxyphenyl)ethyl]
(methyl)amino}626(propan626
yl)pentanenitrile 
 
3.8 
 
L6type Ca2+ 
channel 
Nifedipine 3,56dimethyl 2,66dimethyl646
(26nitrophenyl)61,46
dihydropyridine63,56
dicarboxylate 
 
2.2 
 
L6type Ca2+ 
channel 
Disopyramide (RS)646[bis(propan626
yl)amino]626phenyl626
(pyridin626yl)butanamide 
 
2.6 
 
Na+ channels 
Procainamide 46amino6*6[26
(diethylamino)ethyl] 
benzamide 
 
0.9 
 
Na+ channels 
Flecainide (RS)6*6(piperidin626
ylmethyl)62,56bis(2,2,26
trifluoroethoxy) 
benzamide 
 
3.8 
 
Na+ channels 
Etomoxir ethyl 26[66(46
chlorophenoxy)hexyl] 
oxirane626carboxylate 
 
4.5 
 
CPT 
Perhexiline 26(2,26dicyclohexylethyl) 
piperidine 
 
6.2 
 
See Table 1 
Oxfenicine (2S)626amino626(46
hydroxyphenyl)acetic acid 
 
0.2 
 
CPT? 
Dofetilide *6[46(26{[26(46
methanesulfonamidophenyl)
ethyl](methyl)amino}
ethoxy)phenyl]methanesulfo
namide 
 
2.1 
 
K+ channels 
Amiodarone {26[46(26butyl616
benzofuran636
carbonyl)62,666
diidophenoxy]ethyl}
diethylamine 
 
7.6 
 
K+ channels 
 
O 
N 
H 
H 
H 
N 
N 
O O O 
O1 N+ 
O 
O 
H
C 
N 
O 
O 
N 
O 
O 
N 
H 
Cl 
O
O
O
O
H 
N 
N 
O 
N 
H 
O 
N 
O 
I 
I 
O 
O 
N 
N
H
S
O
O
O
O
N
H
S
O 
N 
H 
H 
N 
O 
O 
F F 
F F 
F 
O 
H 
N 
H H 
O 
O 
H 
Table 2. Chemical names, structures and logP values of Ca2+1, Na+1, K+1channel and CPT 
inhibitors. 
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Figure 1. Endogenous inhibition of CPT11 by malonyl1CoA 
Studies using 13C6radiolabelled etomoxir as a probe for CPT distribution revealed that in the 
heart, CPT61 is expressed to higher levels than CPT2.50 This raises the possibility that not all 
CPT1 is ‘paired’ with CPT2 as is depicted here. CPT61B is the predominant cardiac isoform 
and is more sensitive to malonyl co6A inhibition than CPT61A (IC50 of 0.03QM vs. 0.361QM, 
respectively)49.  
GLUT, glucose transporter; G6P, glucose666phosphate; LDH, lactose dehydrogenase; 
FATP, fatty acid transporter protein; MCT, monocarboxylase transporter; PDC, pyruvate 
dehydrogenase complex, β6ox, β6oxidation; CPT61, carnitine palmitoyltransferase 1; CPT62, 
carnitine palmitoyltransferase 2; CTP, citrate transporter protein; ACC, acetyl6CoA 
carboxylase; MCD, malonyl6CoA decarboxylase; IMM, inner mitochondrial membrane; 
OMM, outer mitochondrial membrane. 
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Figure 2. Modes of cellular accumulation of PHX 
At pH7.4 approximately 99.9% of PHX would exist in the cationic form in equilibrium with 
approximately 0.1% as the neutral species. As described in section 5, organic ion 
transporter proteins (TP) probably play an important role in the active uptake and 
intracellular accumulation of PHX, as has been described for amiodarone.113 
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(A) Increased cytoplasmic [PHX] and high intracellular concentrations of ‘free’ (unbound) 
PHX would not be possible under equilibrium conditions if plasma [PHX] was maintained at 
much lower levels. 
(B) Cellular accumulation of PHX could occur if PHX bound with reasonably high affinity to a 
cytoplasmic target / binding partner. 
(C) Selective accumulation of PHX by direct binding to its reported targets (see Table 1). 
(D) Heterogeneous distribution of PHX via partitioning of neutral and cationic species of drug 
into mitochondrial membranes which promotes high localized concentrations around CPT61. 
Some [PHX] in the cytoplasm available to interact with surface membrane ion channels and, 
over time, accumulate in pericardial fat. 
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